Zacks Investment Research on MSN
Three genomics stocks worth tracking this year
An updated edition of the Nov. 18, 2025, article. Genomics is a broad and detailed study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
GEN’s first virtual event of 2026—we present a group of outstanding researchers and thought-leaders to discuss the latest advances and challenges in delivering genetic therapies.
A preclinical study uncovered a new gene therapy that targets pain centers in the brain while eliminating the risk of ...
News-Medical.Net on MSN
Gene therapy breakthrough could provide hope for millions living with chronic pain
A preclinical study uncovered a new gene therapy that targets pain centers in the brain while eliminating the risk of ...
News Medical on MSN
CIRM awards $7.4 million to advance stem cell-based gene therapy for Friedreich's ataxia
The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for ...
News Medical on MSN
American Society of Gene & Cell Therapy and Orphan Therapeutics Accelerator partner to advance and commercialize promising rare disease treatments
The American Society of Gene & Cell Therapy (ASGCT), the leading professional organization for the advancement of cell and gene therapies (CGTs), and the Orphan Therapeutics Accelerator (OTXL), a ...
11hon MSN
How major nuclear protein complexes control specialized gene regulation in cancer and beyond
Precision and timing of gene expression is essential for normal biological functions and, when disrupted, can lead to many ...
Pharmacogenetics and pharmacogenomics are increasingly recognised as playing a pivotal role in the advancement of personalised medicine, especially in the ...
The firm plans to enroll US patients into the trial of GEB-101 in the second quarter, having launched an investigator-initiated trial in China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results